Tenaya therapeutics receives orphan drug designation from the u.s. food and drug administration for its gene therapy for genetic arrhythmogenic right ventricular cardiomyopathy

Tn-401 is being developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (arvc) caused by mutations in the pkp2 gene

TNYA Ratings Summary

TNYA Quant Ranking